|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Microproteinuria in patients with inflammatory bowel disease:Is it associated with the disease activity or the treatment with 5-aminosalicylic acid?显示文摘瞄准:调查在有煽动性的肠疾病(IBD ) 的病人的 microproteinuria 是否与 5-aminosalicylic 酸(5-ASA ) 与疾病活动或治疗被联系。方法:我们有希望地与 IBD 在 86 个连续病人学习了 microproteinuria, 61 与 ulcerative (UC ) 并且 25 与 Crohn 的疾病(CD ) ,以前象在他们在学习的包括以后的 2 和 6 个月一样。46 个病人为 28.8 个月(范围 1-168 瞬间) 的一个时期收到了 5-ASA。Microalbuminuria (妈磅) 和尿肾的管状的蛋白质 beta2-microglobulin (beta2mGLB ) 和 beta-N-acetyl-D-glucosamidase 铺平(贝它 -- 唠叨) 一夜间在 12-h 象 creatinine 一样被决定尿收集。肿瘤坏死 factor-alpha (TNF-alpha ) 浆液层次也被测量。结果:277 大小的一个总数(194 在 UC 病人并且 83 在 CD 病人) 被执行。在 UC 和 CD 病人的反常 microproteinuria 的流行为妈磅是 12.9% 和 6.0% , 22.7% 和 27.7% 为 beta2mGLB,并且 11.3% 和 8.4% 为贝它 -- 分别地唠叨。妈磅没与 IBD 活动被联系。Beta2mGLB 和贝它 -- 唠叨尿层次被相关到 UC 活动(UCAI:P<0.01;UCEI:P<0.005 ) 。在 UC 病人和贝它的妈磅 -- 在 CD 病人唠叨尿层次与 TNF-alpha 浆液层次有关。一个协会在 microproteinuria 和吸烟习惯之间被注意。有 5-ASA 的治疗没被相关到 microproteinuria 的严厉或到 creatinine 的变化。结论:Microproteinuria 主要与 UC 和它的活动被联系然而并非由 5-ASA 影响了。 | Androniki C Poulou Konstantinos E Goumas Dimitrios C Dandakis Ioannis Tyrmpas Maria Panagiotaki Androniki Georgouli Dimitrios C Soutos Athanasios Archimandritis | 2006 | World Journal of Gastroenterology2006，12，5： | 126 |
| 2 | MELD vs Child-Pugh and creatinine-modified Child-Pugh score for Dredicting survival in patients with decompensated cirrhosis显示文摘AIM: Model of End-stage Liver Disease (MELD) score has recently gained wide acceptance over the old Child-Pugh score in predicting survival in patients with decompensated cirrhosis, although it is more sophisticated. We compared the predictive values of MELD, Child-Pugh and creatinine modified Child-Pugh scores in decompensated cirrhosis. METHODS: A cohort of 102 patients with decompensated cirrhosis followed-up for a median of 6 mo was studied.Two types of modified Child-Pugh scores estimated by adding 0-4 points to the original score using creatinine levels as a sixth categorical variable were evaluated.RESULTS: The areas under the receiver operating characteristic curves did not differ significantly among the four scores, but none had excellent diagnostic accuracy (areas:0.71-0.79). Child-Pugh score appeared to be the worst, while the accuracy of MELD was almost identical with that of modified Child-Pugh in predicting short-term and slightly better in predicting medium-term survival. In Cox regression analysis, all four scores were significantly associated with survival, while MELD and creatinine-modified Child-Pugh scores had better predictive values (c-statistics: 0.73 and 0.69-0.70) than Child-Pugh score (c-statistics: 0.65). Adjustment for gamma-glutamate transpeptidase levels increased the predictive values of all systems (c-statistics: 0.77-0.81). Analysis of the expected and observed survival curves in patients subgroups according to their prognosis showed that all models fit the data reasonably well with MELD probably discriminating better the subgroups with worse prognosis. CONCLUSION: MELD compared to the old Child-Pugh and particularly to creatinine-modified Child-Pugh scores does not appear to offer a clear advantage in predicting survival in patients with decompensated cirrhosis in daily clinical practice. | George V. Papatheodoridis Evangelos Cholongitas Eleni Dimitriadou Giota Touloumi Vassilios Sevastianos Athanasios J. Archimandritis | 2005 | World Journal of Gastroenterology2005，11，20： | 30 |
| 3 | Role of soluble triggering receptor expressed on myeloid cells in inflammatory bowel disease显示文摘瞄准:为了调查可溶的被触发的可能的角色,受体在煽动性的肠疾病(IBD ) 的致病在骨髓的上表示了 cells-1 (sTREM-1 ) 。方法:58 个病人被注册;十九个健康志愿者用作控制;8 个病人与 Crohn 的疾病被诊断,并且 31 与 ulcerative。有 Crohn 的疾病和 ulcerative 的病人的临床、内视镜的活动索引分别地被估计。在承认之上,血被取样;sTREM-1 和 TNFalpha 被 thiobarbitourate 试金被免疫分析和 malondialdehyde (MDA ) 测量,在通过一个 HPLC 系统的经过以后。结果:控制,有 Crohn 的疾病的病人和有 ulcerative 的病人的 TNFalpha 的中部的 +/- SE 是 6.02 +/- 3.94, 7.98 +/- 5.08 (P = NS 对控制) ,并且 8.45 +/- 4.15 ng/L (P = 0.018 对控制) 分别地。sTREM-1 的各自的价值是 53.31 +/- 32.93, 735.10 +/- 197.17 (P = 0.008 对控制) 并且 435.82 +/- 279.71 ng/L (P = 0.049 对控制) 。sTREM-1 断然与 Crohn 的疾病活动索引和 ulcerative 的临床、内视镜的活动索引被相关(P = 0.002, 0.001 和 0.009,分别地) 。有 ulcerative 的病人的 sTREM-1 断然与 TNFalpha 被相关(P = 0.001 ) 。结论:sTREM-1 似乎在与肠粘膜的炎性反应的度的关联在 IBD 作为一个新奇调停人表现。 | Michalis Tzivras Vassilios Koussoulas Evangelos J Giamarellos-Bourboulis Dimitrios Tzivras Thomas Tsaganos Pantelis Koutoukas Helen Giamarellou Athanasios Archimandritis | 2006 | World Journal of Gastroenterology2006，12，21： | 17 |
| 4 | Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C显示文摘Classical interferon-alpha has been shown to be correlated with the development of a variety of autoimmune disorders. A 38 year-old female patient developed simultaneously diabetic ketoacidosis and hyperthyroidism 5 mo following initiation of treatment with pegylated interferon-α and ribavirin for chronic hepatitis C. High titers of glutamic acid decarboxylase, antinuclear and thyroid (thyroid peroxidase and thyroglobulin) antibodies were detected. Antiviral treatment was withdrawn and the patient was treated with insulin for insulin-dependent diabetes mellitus and propranolol for hyperthyroidism. Twelve months after cessation of pegylated interferon-α therapy the patient was euthyroid without any medication but remained insulin-dependent. | Aspasia S Soultati Spyridon P Dourakis Alexandra Alexopoulou Melanie Deutsch Athanasios J Archimandritis | 2007 | World Journal of Gastroenterology2007，13，8： | 15 |
| 5 | Role of Helicobacter pylorieradication in aspirin or non-steroidal anti-inflammatory drug users显示文摘Helicobacter pylori (H pylori) infection and the use of nonsteroidal anti-inflammatory drugs (NSAIDs) including aspirin at any dosage and formulation represent well-established risk factors for the development of uncomplicated and complicated peptic ulcer disease accounting for the majority of such cases. Although the interaction between H pylori and NSAID/aspirin use in the same individuals was questioned in some epidemiological studies, it has now become widely accepted that they are at least independent risk factors for peptic ulcer disease. According to data from randomized intervention trials, naive NSAID users certainly benefit from testing for H pylori infection and, if positive,H pylori eradication therapy prior to the initiation of NSAID. A similar strategy is also suggested for naive aspirin users, although the efficacy of such an approach has not been evaluated yet. Strong data also support that chronic aspirin users with a recent ulcer complication should be tested for H pyloriinfection and, if positive, receive H pylori eradication therapy after ulcer healing, while they appear to benefit from additional long-term therapy with a proton pump inhibitor (PPI).A similar approach is often recommended to chronic aspirin users at a high risk of ulcer complication. H pylori eradication alone does not efficiently protect chronic NSAID users with a recent ulcer complication or those at a high-risk, who certainly should be treated with long-term PPI therapy, but H pylori eradication may be additionally offered even in this setting. In contrast, testing for H pylorior PPI therapy is not recommended for chronic NSAID/aspirin users with no ulcer complications or those at a low risk of complications. | George V. Papatheodoridis Athanasios J. Archimandritis | 2005 | World Journal of Gastroenterology2005，11，25： | 8 |
| 6 | Liver histology in ICU patients dying from sepsis:A clinico-pathological study显示文摘AIM:To determine end-stage pathologic changes in the liver of septic patients dying in the intensive care unit. METHODS: Needle liver biopsies obtained immediately after death from 15 consecutive patients with sepsis and no underlying liver disease were subjected to routine histological examination. Liver function tests and clinical monitoring measurements were also recorded. RESULTS: Liver biochemistries were increased in the majority of patients before death. Histology of liver bi- opsy specimens showed portal inflammation in 73.3%, centrilobular necrosis in 80%, lobular inflammation in 66.7%, hepatocellular apoptosis in 66.6% and cholan- gitis/cholangiolitis in 20% of patients. Mixed hepatitic/ cholestatic type of liver injury was observed in 6/15 (40%) patients and hepatitc in 9/15 (60%). Steatosis was ob- served in 11/15 (73.3%) patients affecting 5%-80% of liver parenchyma. Among the histological features, the presence of portal inflammation in liver biopsy was as- sociated with increased hospitalization in the ICU prior death (P = 0.026). CONCLUSION: Features of hepatitis and steatosis arethe main histological findings in the liver in the majority of patients dying from sepsis. | John Koskinas Ilias P Gomatos Dina G Tiniakos Nikolaos Memos Maria Boutsikou Aspasia Garatzioti Athanasios Archimandritis Alexander Betrosian | 2008 | World Journal of Gastroenterology2008，14，9： | 8 |
| 7 | Retinol-binding protein, acute phase reactants and Helicobacter pylori infection in patients with gastric adenocarcinoma显示文摘AIM: To determine the serum levels of c-reactive protein (CRP), transferrin (TRF), a2-macroglobulin (A2M),ceruloplasmin (CER), a1-acid glycoprotein (AAG), prealbumin (P-ALB) and retinol-binding protein (RBP) in gastric carcinoma patients and to explore their possible correlation with underlying Helicobacter pylori (H pylon)infection.METHODS: We measured the serum levels of CRP, TRF,A2M, CER, AAG, P-ALB, and RBP in 153 preoperative patients (93 males; mean age: 63.1±11.3 years) with non-cardia gastric adenocarcinoma and 19 healthy subjects.RESULTS: The levels of CRP, CER, RBP, andAAG in cancer patients were significantly higher than those in healthy controls (P<0.0001), while no difference was found regarding the TRF, P-ALB, and A2M levels. Cancer patients with H pylori infection had significantly lower RBP values compared to non-infected ones (P<0.0001)and also higher values of CRP and AAG (P = 0.09 and P = 0.08, respectively).CONCLUSION: High serum levels of CRP, CER and AAG in cancer patients do not seem to be related to H pylori infection. Retinol-binding protein seems to discriminate between infected and non-infected patients with gastric carcinoma. Further studies are needed to explore if it is directly involved in the pathogenesis of the disease or is merely an epiphenomenon. | Nicolas Tsavaris Christos Kosmas Petros Kopterides Dimitrios Tsikalakis Hlias Skopelitis Fotini Sakelaridi Nikitas Papadoniou Michalis Tzivras Vasilios Balatsos Christos Koufos Athanasios Archimandritis | 2005 | World Journal of Gastroenterology2005，11，45： | 7 |
| 8 | Current treatment indications and strategies in chronic hepatitis B virus infection显示文摘The optimal approach to the management of several marginal cases with chronic hepatitis B virus (HBV) infection is controversial. Serum HBV DNA and ami-notransferase levels, and the degree of necroinflammation and fibrosis determine the therapeutic decisions. All patients with elevated aminotransferase (> twice the upper limit of normal) and serum HBV DNA above 20 000 IU/mL should be treated. Liver biopsy is important for therapeutic decisions in cases with mild aminotransferase elevations and serum HBV DNA below 20 000 IU/mL. Chronic HBV patients who do not receive treatment should be followed for life. There are seven agents licensed for chronic hepatitis B: standard and pegylated interferon-alpha, lamivudine, adefovir, entecavir, telbivudine and tenofovir. One-year courses with pegylated interferon-alpha induce sustained off-therapy remission in 30%-32% of patients with HBeAg-positive chronic hepatitis B and in a smaller proportion of patients with HBeAg-negative chronic hepatitis B. Oral antivirals achieve initial on-therapy responses in the majority of patients, but are intended as long-term therapies. Viral suppression has favourable effects on patients' outcome and modifies the natural course of the disease. Viral resistance, however, is the major drawback of long-term oral antiviral therapy. Lamivudine monotherapy is associated with the highest and ente-cavir monotherapy with the lowest resistance rate so far. There has been no resistance to tenofovir, but afteronly 18 mo of treatment to date. The optimal first-line anti-HBV therapy with the best long-term cost/benefit ratio remains unclear. If oral antiviral agents are used, compliance should always be ascertained and HBV DNA levels should be regularly tested. | George V Papatheodoridis Spilios Manolakopoulos Athanasios J Archimandritis | 2008 | World Journal of Gastroenterology2008，14，45： | 7 |
| 9 | Cholangiocarcinoma:A 7-year experience at a single center in Greece显示文摘AIM: To evaluate survival rate and clinical outcome of cholangiocarcinoma.METHODS: The medical records of 34 patients with cholangiocarcinoma,seen at a single hospital between the years 1999-2006,were retrospectively reviewed.RESULTS: Thirty-four patients with a median age of 75 years were included.Seventeen (50%) had painless jaundice at presentation.Sixteen (47.1%) were perihilar,15 (44.1%) extrahepatic and three (8.8%) intrahepatic.Endoscopic retrograde cholangiography (ERCP) and/or magnetic resonance cholangiography (MRCP) were used for the diagnosis.Pathologic confirmation was obtained in seven and positive cytological examination in three.Thirteen patients had co-morbidities (38.2%).Four cases were managed with complete surgical resection.All the rest of the cases (30) were characterized as non-resectable due to advanced stage of the disease.Palliative biliary drainage was performed in 26/30 (86.6%).The mean follow-up was 32 mo (95% CI,20-43 mo).Overall median survival was 8.7 mo (95% CI,2-16 mo).The probability of 1-year,2-year and 3-year survival was 46%,20% and 7%,respectively.The survival was slightly longer in patients who underwent resection compared to those who did not,but this difference failed to reach statistical significance.Patients who underwent biliary drainage had an advantage in survival compared to those who did not (probability of survival 53% vs 0% at 1 year,respectively,P = 0.038).CONCLUSION: Patients with cholangiocarcinoma were usually elderly with co-morbidities and/or advanced disease at presentation.Even though a slight amelioration in survival with palliative biliary drainage was observed,patients had dismal outcome without resection of the tumor. | Alexandra Alexopoulou Aspasia Soultati Spyros P Dourakis Larissa Vasilieva Athanasios J Archimandritis | 2008 | World Journal of Gastroenterology2008，14，40： | 3 |
| 10 | Therapeutic strategies in the management of patients with chronic hepatitis B virus infection显示文摘 | George V Papatheodoridis Spilios Manolakopoulos Geoffrey Dusheiko Athanasios J Archimandritis | 2008 | The Lancet Infectious Diseases2008，，3： | 2 |
| 11 | Therapeutic strategies in the management of patients with chronic hepatitis B virus infection显示文摘 | George V Papatheodoridis Spilios Manolakopoulos Geoffrey Dusheiko Athanasios J Archimandritis | 2008 | The Lancet Infectious Diseases2008，，3： | 2 |
| 12 | Adipokines in Nonalcoholic Steatohepatitis: From Pathogenesis to Implications in Diagnosis and Therapy显示文摘 | Emmanuel A. Tsochatzis George V. Papatheodoridis Athanasios J. Archimandritis Fulvio D’Acquisto | 2009 | Mediators of Inflammation2009，，： | 2 |
| 13 | Therapeutic strategies in the management of patients with chronic hepatitis B virus infection显示文摘 | George V Papatheodoridis Spilios Manolakopoulos Geoffrey Dusheiko Athanasios J Archimandritis | 2008 | The Lancet Infectious Diseases2008，，3： | 1 |
| 14 | B2 microglobulin: is it a reliable marker of activity in inflammatory bowel disease?显示文摘 | Miltiadis Zissis Angelos Afroudakis George Galanopoulos Ioannis Palermos Xanthi Boura Spyros Michopoulos Athanasios Archimandritis | 2001 | The American Journal of Gastroenterology2001，，7： | 1 |
| 15 | Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension显示文摘 | Spilios Manolakopoulos Christos Triantos Jiannis Theodoropoulos Jiannis Vlachogiannakos Anastasios Kougioumtzan George Papatheodoridis Dimitrios Tzourmakliotis Dimitrios Karamanolis Andrew K. Burroughs Athanasios Archimandritis Sotirios Raptis Alec Avgeri | 2009 | Journal of Hepatology2009，，3： | 1 |
| 16 | Natural History of Chronic Hepatitis B Virus Infection in Children of Different Ethnic Origins: A Cohort Study with Up to 12 Years? Follow-up in Northern Greece显示文摘 | George Zacharakis John Koskinas Stamatia Kotsiou Evaggelia Pouliou Menelaos Papoutselis Fevronia Tzara Nikolaos Vafeiadis Eustratios Maltezos Athanasios Archimandritis Kostantinos Papoutselis | 2007 | Journal of Pediatric Gastroenterology and Nutrition2007，，1： | 1 |
| 17 | Adipokines in Nonalcoholic Steatohepatitis: From Pathogenesis to Implications in Diagnosis and Therapy显示文摘 | Emmanuel A. Tsochatzis George V. Papatheodoridis Athanasios J. Archimandritis Fulvio D'Acquisto | 2009 | Mediators of Inflammation2009，，： | 1 |
| 18 | Primary Hepatic Actinomycosis Mimicking Metastatic Liver Tumor显示文摘 | Theoni Kanellopoulou Alexandra Alexopoulou Dina Tiniakos John Koskinas Athanasios J. Archimandritis | 2010 | Journal of Clinical Gastroenterology2010，，6： | 1 |
| 19 | Light chain multiple myeloma in a patient with long-standing rheumatoid arthritis显示文摘 | Alexandra Alexopoulou Spyros P. Dourakis Alexandra Apostolopoulou Anna Kandyli Helen Pandelidaki Athanasios J. Archimandritis | 2005 | Clinical Rheumatology2005，，6： | 1 |
| 20 | The burden and recent epidemiological changes of the main chronic liver diseases in a Greek referral tertiary centre显示文摘 | Ioannis P. Giannousis George V. Papatheodoridis Melanie J. Deutsch Spilios G. Manolakopoulos Emanuel K. Manesis John S. Koskinas Athanasios J. Archimandritis | | European Journal of Gastroenterology & Hepatology0，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员